Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

The oncologist - 1 Jan 2011

Deenen Maarten J, Cats Annemieke, Beijnen Jos H, Schellens Jan H M

Abstract excerpt

Equivalent drug doses may lead to wide interpatient variability in drug response to anticancer therapy. Known determinants that may affect the pharmacological response to a drug are, among others, nongenetic factors, including age, gender, use of comedication, and liver and renal function. Nonetheless, these covariates do not explain all the observed interpatient variability. Differences in genetic constitution...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Genetic Variation
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 21659608
DOI: 10.1634/theoncologist.2010-0260
PMCID: PMC3228134

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.PMID 21659608Read ↗

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Semantic proximity Read ↗

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Semantic proximity Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of Drugs Used in the Treatment of CancersSemantic proximity Read ↗

Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Semantic proximity Read ↗

Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.Semantic proximity Read ↗

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Semantic proximity Read ↗

Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsSemantic proximity Read ↗

[Pharmacogenetics of anticancer drugs].Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.Semantic proximity Read ↗

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Semantic proximity Read ↗

Pharmacogenomics in cancer therapy: is host genome variability important?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.